Flagship Harbor Advisors LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.8% during the first quarter, Holdings Channel reports. The institutional investor owned 2,118 shares of the medical instruments supplier’s stock after selling 229 shares during the period. Flagship Harbor Advisors LLC’s holdings in Becton, Dickinson and were worth $389,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares during the last quarter. Finally, Fundsmith LLP increased its stake in shares of Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares during the last quarter. Institutional investors and hedge funds own 75.57% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down 0.99% during trading on Friday, reaching $197.33. 256,973 shares of the company’s stock traded hands. The company has a 50 day moving average price of $199.60 and a 200-day moving average price of $188.53. The stock has a market cap of $44.91 billion, a P/E ratio of 57.15 and a beta of 1.05. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the prior year, the firm posted $2.35 EPS. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/18/flagship-harbor-advisors-llc-has-389000-position-in-becton-dickinson-and-company-bdx.html.

A number of analysts have recently issued reports on the stock. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and raised their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 price target (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Finally, Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,631 shares of company stock worth $11,112,178. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.